HSV G207

P2, N=35, Suspended, Pediatric Brain Tumor Consortium | Recruiting --> Suspended

P1, N=24, Recruiting, M.D. Anderson Cancer Center | Active, not recruiting --> Recruiting

P2, N=35, Recruiting, Pediatric Brain Tumor Consortium | Trial completion date: Feb 2029 --> Feb 2030 | Trial primary completion date: Dec 2028 --> Dec 2029

P2, N=40, Recruiting, Pediatric Brain Tumor Consortium | Not yet recruiting --> Recruiting

P1, N=24, Active, not recruiting, Gregory K. Friedman, MD | Trial completion date: Sep 2026 --> Sep 2027 | Trial primary completion date: Sep 2025 --> Sep 2026

P1, N=24, Active, not recruiting, Gregory K. Friedman, MD | Recruiting --> Active, not recruiting | N=15 --> 24

P1, N=13, Completed, Gregory K. Friedman, MD | Active, not recruiting --> Completed

RNA sequencing of control cells and cells treated for 8 and 24 h revealed that there were few shared differentially expressed (DE) genes between cells treated with PVSRIPO and G207: GCLM, LANCL2, and RBM3 were enriched whilst ADAMTS1 and VEGFA were depleted. Likewise, there were few shared DE genes enriched between medulloblastoma and high-grade glioma cell lines treated with G207: GPSM2, CHECK2, SEPTIN2, EIF4G2, GCLM, GDAP1, LANCL2, and PWP1.  Treatment with G207 and PVSRIPO appear to cause disparate gene enrichment and depletion suggesting disparate molecular mechanisms in malignant pediatric brain tumors.

P2, N=40, Active, not recruiting, Pediatric Brain Tumor Consortium | Not yet recruiting --> Active, not recruiting

We reviewed seven virus types that have been investigated in past or ongoing pediatric tumor clinical trials: adenovirus (AdV-tk, Celyvir, DNX-2401, VCN-01, Ad-TD-nsIL-12), herpes simplex virus (G207, HSV-1716), vaccinia (JX-594), reovirus (pelareorep), poliovirus (PVSRIPO), measles virus (MV-NIS), and Senecavirus A (SVV-001). However, the antitumor effects of OVT remain variable depending on tumor type and viral agent used. Although the widespread adoption of OVT faces many challenges, we are optimistic that OVT will play an important role alongside standard chemotherapy and radiotherapy for the treatment of malignant pediatric solid tumors in the future.

P2, N=40, Not yet recruiting, Pediatric Brain Tumor Consortium | Trial completion date: Apr 2028 --> Nov 2028 | Trial primary completion date: Apr 2028 --> Nov 2028

Toxicity from intraventricular oHSV can be mitigated resulting in therapeutic benefit. These data support clinical translation of intraventricular G207.